Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.  Laurence Belkoff, DO, FACOS, Chairman of the Department of Specialty Surgeries and the Division of Urology at the Philadelphia College of Osteopathic Medicine presented the results during the late-breaking science forum. The top-line results had been previously reported; however, the presentation by Dr. Belkoff marks the first time these results have been presented at a major medical meeting.

The study met all primary endpoints by demonstrating sustained improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvements in the International Index of Erectile Function (IIEF).  The study also indicated that successful intercourse (as measured by SEP 3) was achieved as early as 15 minutes, consistent with results from previously reported phase 3 double-blind, placebo-controlled studies.

"The avanafil data from the open label, long-term safety study confirm the safety and efficacy results previously observed in the two placebo-controlled trials," commented Dr. Belkoff.  "The safety profile demonstrated during the year-long study and successful intercourse attempts within 15 minutes of dosing suggest avanafil, if approved, may be an attractive treatment option for men with ED."

Highlights of the TA-314 study include:

  • Eighty percent (80%) of sexual attempts among patients on avanafil resulted in erections sufficient for intercourse (SEP 2)
  • Erectil
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
    (Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
    (Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
    Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
    ... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
    ... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
    Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
    (Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
    (Date:4/25/2015)... (PRWEB) April 25, 2015 The ... vaginal mesh lawsuits filed against C.R. Bard, Inc. ... Court, Southern District of West Virginia. According to ... Conference was convened that day, after certain defendants ... Form Complaint. The Order directed that any Preliminary ...
    (Date:4/25/2015)... BWI (PRWEB) April 25, 2015 An ... celebrated three months of successfully welcoming visitors to the ... 2015. , As part of a major construction ... airport was completely redesigned to speed up arrivals. ... process of getting out of the airport and onto ...
    (Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse ... case with the Miami Dolphins and Richie Incognito, or off the ... Rice domestic abuse case. In a recent episode of SCI ... implications of locker room culture on teams. He examines what worked ... do to improve the locker room as a work place. ...
    (Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
    Breaking Medicine News(10 mins):Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
    ... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
    ... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
    ... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
    ... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
    ... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
    ... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
    Cached Medicine News:
    ... includes everything from the care package ... Spare Fluorescent Bulb, additional Vibratome Feather ... and a Specimen Tray. ... 1/2" speciment mounts, replacement rotating mounts, ...
    ... The Specimen Tray accessory fits inside the ... removable working area for tissue sectioning. Specimens ... specimen tray. This is a great option ... an expensive buffer, or wish to utilize the ...
    ... inside the existing black Vibratome bath. This ... buffer and ice kept in the original black ... has round mounting disks that can be easily ... bath surface are marked with degrees of rotation ...
    ... This unit provides a convenient reservoir of cooling ... operated for an extended period of time or in ... nearby to cool the hot side of the thermoelectric ... of water, which is adequate to run the 900R ...
    Medicine Products: